Limits...
OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review

View Article: PubMed Central - PubMed

ABSTRACT

Objective: This systematic review was performed to elucidate dosing practices, dosing conversions, and related outcomes from randomized, controlled trials that directly compared onabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO) at various dose conversion ratios for therapeutic use in movement disorders.

Methods: A systematic review of three medical literature databases (PubMed, the Cochrane Library, and EMBASE) was performed to identify relevant comparative clinical studies, systematic reviews, and meta‐analyses published in the English language between January 1991 and January 2015. Studies that met predefined inclusion criteria were selected for formal data extraction and quality assessment.

Results: A total of 182 manuscripts were identified, of which four were included for analysis. Targeted clinical applications included neurological disorders. The studies compared ONA to ABO dose conversion ratios of 1:2.5 (n = 1), 1:3 (n = 2), and 1:4 (n = 2). One study compared both 1:3 and 1:4 ratios. An ONA:ABO conversion factor of 1:2.5 was associated with similar efficacy and side effects. An ONA:ABO ratio of 1:3 provided similar or higher efficacy, but an increased rate of adverse effects, and an ONA:ABO ratio of 1:4 was associated with higher efficacy, but with an excessive rate of intolerable side effects.

Conclusion: A dose conversion ratio of ONA to ABO between 1:2.5 and 1:3.0 provides comparable safety and efficacy for therapeutic movement disorders chemodenervation procedures.

No MeSH data available.


Distribution of studies by indication, dose conversion ratio, and outcomes. Note: the sizes of the circles reflect number of subjects in each study.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836618&req=5

mdc312235-fig-0002: Distribution of studies by indication, dose conversion ratio, and outcomes. Note: the sizes of the circles reflect number of subjects in each study.

Mentions: The outcomes of the clinical trials by dose conversion ratio and indication are shown in Figure 2. The two randomized, clinical trials (total, n = 264) that compared ONA and ABO at a dose conversion ratio of 1:4 were both associated with greater occurrence of adverse effects with ABO.22, 24 In one of the trials (n = 73) that used a 1:3 dose conversion, efficacy and safety did not differ between ABO and ONA.21 In the other trial (n = 51) that used a 1:3 dose conversion, treatment with ABO resulted in higher efficacy and higher rates of adverse events.22 In the trial (n = 103) that used a 1:2.5 dose conversion, ABO was associated with similar efficacy and adverse events.23


OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review
Distribution of studies by indication, dose conversion ratio, and outcomes. Note: the sizes of the circles reflect number of subjects in each study.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836618&req=5

mdc312235-fig-0002: Distribution of studies by indication, dose conversion ratio, and outcomes. Note: the sizes of the circles reflect number of subjects in each study.
Mentions: The outcomes of the clinical trials by dose conversion ratio and indication are shown in Figure 2. The two randomized, clinical trials (total, n = 264) that compared ONA and ABO at a dose conversion ratio of 1:4 were both associated with greater occurrence of adverse effects with ABO.22, 24 In one of the trials (n = 73) that used a 1:3 dose conversion, efficacy and safety did not differ between ABO and ONA.21 In the other trial (n = 51) that used a 1:3 dose conversion, treatment with ABO resulted in higher efficacy and higher rates of adverse events.22 In the trial (n = 103) that used a 1:2.5 dose conversion, ABO was associated with similar efficacy and adverse events.23

View Article: PubMed Central - PubMed

ABSTRACT

Objective: This systematic review was performed to elucidate dosing practices, dosing conversions, and related outcomes from randomized, controlled trials that directly compared onabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO) at various dose conversion ratios for therapeutic use in movement disorders.

Methods: A systematic review of three medical literature databases (PubMed, the Cochrane Library, and EMBASE) was performed to identify relevant comparative clinical studies, systematic reviews, and meta‐analyses published in the English language between January 1991 and January 2015. Studies that met predefined inclusion criteria were selected for formal data extraction and quality assessment.

Results: A total of 182 manuscripts were identified, of which four were included for analysis. Targeted clinical applications included neurological disorders. The studies compared ONA to ABO dose conversion ratios of 1:2.5 (n = 1), 1:3 (n = 2), and 1:4 (n = 2). One study compared both 1:3 and 1:4 ratios. An ONA:ABO conversion factor of 1:2.5 was associated with similar efficacy and side effects. An ONA:ABO ratio of 1:3 provided similar or higher efficacy, but an increased rate of adverse effects, and an ONA:ABO ratio of 1:4 was associated with higher efficacy, but with an excessive rate of intolerable side effects.

Conclusion: A dose conversion ratio of ONA to ABO between 1:2.5 and 1:3.0 provides comparable safety and efficacy for therapeutic movement disorders chemodenervation procedures.

No MeSH data available.